Microbiome Analysis May Be a Feasible Diagnostic Test for Prostate Cancer
The microbiome could have a role in the diagnosis of PrCa.
Prostate Cancer
Tertiary Gleason Pattern 5 Ups BCR Risk After Radical Prostatectomy
In a study of radical prostatectomy patients with Gleason score 7 prostate cancer, the risk for biochemical recurrence more than doubled in the presence of tertiary pattern 5 disease.
Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either.
Adjusting the Risk Calculation for Biopsy-Detectable Prostate Cancer
Researchers sought to demonstrate how recalibration of risk stratification tools can improve accuracy and clinical decision making.
Rural Patients May Be Less Likely to Receive Treatment for Prostate Cancer
Simply living in a rural area made it less likely an individual with prostate cancer to receive treatment, with the exception of radiation.
Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems.
Metastatic Site Predicts Death Risk in Advanced Prostate Cancer
A recent study of men with stage IV prostate cancer revealed that liver-only metastasis is associated with worse cancer-specific and overall survival than bone-only and lung-only metastasis
CVD Prior to Oral Antiandrogen Therapy for Prostate Cancer Increases Mortality Risk
In a study, men who had pre-existing cardiovascular disease prior to taking abiraterone or enzalutamide for advanced prostate cancer had a 16% to 56% increased 6-month risk.
FDA: Entacapone Not Associated With Increased Prostate Cancer Risk
The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
Skeletal-Related Events Common After CRPC Development
Large observational study reveals a 40% cumulative incidence rate of first skeletal-related events following development of castration-resistant prostate cancer.
Next post in Prostate Cancer
